Paclitaxel-Associated Immediate Hypersensitivity Reactions: Incidence, Severity, and Clinical Management in a Tertiary Care Hospital

Cancer treatment frequently requires combination regimens in which the therapeutic benefit of antineoplastic medicines must be balanced against treatment-related toxicity. Chemotherapy-related adverse effects may be haematological or non-haematological and can influence treatment continuity, supportive-care requirements, and patient safety. The attached source manuscript identifies breast, lung, colorectal, uterine, thyroid, prostate, and bladder cancers among commonly discussed malignancies and emphasizes the need for careful monitoring of anticancer therapy [4–10].

Paclitaxel is a taxane antineoplastic agent used in several solid tumours, including breast, ovarian, lung, and pancreatic cancers. Its antitumour activity results from binding to the beta-subunit of tubulin, stabilizing microtubules, preventing their depolymerization, and producing cell-cycle arrest at the G2/M phase. The medicine is administered intravenously, is extensively protein-bound, and is metabolized mainly through CYP2C8 with a smaller contribution from CYP3A4. Important adverse effects include myelosuppression, peripheral neuropathy, cardiovascular disturbances, alopecia, mucosal and gastrointestinal effects, and hypersensitivity reactions [3,12,13].

Paclitaxel-associated hypersensitivity reactions can include flushing, pruritus, erythema, facial puffiness, dyspnoea, oxygen desaturation, chest tightness, back pain, cardiovascular instability, or unresponsiveness. The mechanism is not fully defined; however, the solvent Cremophor EL used in conventional paclitaxel formulations has been implicated in non-IgE-mediated mast-cell activation. Reactions are commonly reported during the initial minutes of infusion and are particularly relevant during early treatment cycles. Premedication with a corticosteroid and histamine-receptor antagonists reduces, but does not completely eliminate, the risk [1–3,13,14].

Previous reports cited in the source manuscript describe a variable incidence of paclitaxel hypersensitivity, with rates influenced by formulation, premedication regimen, infusion protocol, allergy history, age, obesity, respiratory dysfunction, and prior reaction. Because the clinical course can differ according to co-administered medicines, rechallenge, desensitization, and formulation, local prospective data are valuable for determining practical monitoring and management requirements.

The present study therefore evaluated immediate hypersensitivity reactions associated with paclitaxel in a tertiary-care setting. The study focused on reaction incidence, timing, severity, demographic and treatment-cycle characteristics, supportive management, and the immediate outcome of continuation, rechallenge, or change of regimen.

2. MATERIALS AND METHODS

2.1 Study design and setting

This prospective observational study was conducted for six months at Sahyadri Super Specialty Hospital, Hadapsar, Pune. The study enrolled 91 patients who collectively received 250 chemotherapy cycles containing intravenous paclitaxel. The work was designed to observe immediate paclitaxel hypersensitivity, document its cycle-level incidence, and describe the management used in routine clinical care.

2.2 Eligibility criteria

Adult patients aged 18 years or older, including geriatric patients, were eligible when they received paclitaxel during the study period. Paediatric patients below 18 years of age were excluded.

2.3 Data collection and clinical observation

A structured form was used to record age, gender, medical history, cancer diagnosis, chemotherapy protocol, relevant laboratory investigations, body surface area, cycle number, and chemotherapeutic prescription details. Patients were observed directly during intravenous paclitaxel administration. The study defined IHRs as reactions occurring during or within one hour after paclitaxel administration, with particular clinical attention to the first minutes of infusion.

2.4 Reaction assessment and management

When an IHR was suspected, the paclitaxel infusion was stopped immediately. Reaction symptoms and severity were assessed using the grading approach stated in the source protocol, and the workflow included WHO causality assessment. Supportive medicines were administered according to the symptoms and clinical severity. After stabilization and recovery, the treating team determined whether paclitaxel could be cautiously restarted or whether the patient should be changed to another regimen.

2.5 Statistical analysis

The collected data were analysed using descriptive statistics. Counts and percentages were used to summarize demographic characteristics, diagnoses, protocol distribution, reaction incidence, reaction timing, severity, management, and outcomes. No additional inferential analysis beyond that reported in the source manuscript was introduced.

 

Figure 2. Gender distribution across the 250 paclitaxel chemotherapy cycles.

 

Figure 3. Age-group distribution across the 250 paclitaxel chemotherapy cycles.

Table 3. Cancer diagnoses represented in paclitaxel chemotherapy cycles

Diagnosis	Cycles, n	Percentage (%)
Breast carcinoma	106	42.4
Oesophageal carcinoma	45	18.0
Ovarian carcinoma	22	8.8
Endometrial carcinoma	20	8.0
Cricopharyngeal carcinoma	14	5.6
Lung carcinoma	13	5.2
Cervical carcinoma	9	3.6
Malignant melanoma	9	3.6
Gastro-oesophageal junction carcinoma	4	1.6
Mucoepidermoid carcinoma	4	1.6
Pancreatic carcinoma	2	0.8
Retromolar trigone metastatic disease	1	0.4
Poorly differentiated squamous cell carcinoma	1	0.4

 

 

Figure 4. Categorization of paclitaxel chemotherapy cycles according to cancer diagnosis.

 

Figure 5. Cycle-level incidence of immediate hypersensitivity reactions to paclitaxel.

 

Figure 6. Distribution of immediate hypersensitivity reactions according to paclitaxel cycle number.

 

Figure 7. Age-group distribution of the eight immediate hypersensitivity reactions.

 

Figure 8. Distribution of the eight immediate hypersensitivity reactions according to body surface area.

 

Figure 9. Distribution of paclitaxel cycles by the three protocol categories reported in the source dataset.

4. DISCUSSION

This prospective observational study documented eight IHRs during 250 paclitaxel chemotherapy cycles, corresponding to a cycle-level incidence of 3.2%. The incidence reported in the source manuscript was lower than the higher rates described in earlier literature, including reports in which hypersensitivity occurred in a substantial proportion of patients before standardized premedication and infusion precautions [1–3,13,14]. The present finding supports the clinical value of premedication and direct observation but also confirms that reactions may still occur despite these preventive measures.

Timing was a prominent feature. Half of all reactions occurred during the first paclitaxel cycle, and the observed clinical events developed within the first 10 minutes of administration. This pattern is consistent with the source manuscript’s background discussion that paclitaxel reactions are commonly concentrated in the first or second exposure and within the initial minutes of infusion. The results therefore support maintaining the greatest level of vigilance at treatment initiation rather than assuming that premedication eliminates risk.

The age and body-surface-area distributions were spread across several categories. Two reactions each occurred in the 31–40, 41–50, and 51–60-year groups, and the body-surface-area distribution was similarly dispersed. Because the study used descriptive analysis and only eight reactions occurred, the supplied results do not establish a single dominant demographic risk group. The practical implication within this dataset is that all patients receiving paclitaxel required observation, rather than monitoring being restricted to a narrowly defined age or body-size category.

All eight reactions were associated with the weekly conventional paclitaxel protocol in the supplied results, whereas no reaction was reported for weekly nab-paclitaxel. The source manuscript relates conventional paclitaxel hypersensitivity to Cremophor EL and notes that formulation and administration rate may influence reaction occurrence. The observed protocol pattern is therefore clinically relevant, although the study results remain descriptive and do not establish a comparative causal effect between formulations.

Clinical manifestations ranged from itching, redness, and puffiness to dyspnoea, oxygen desaturation, facial swelling, sweating, chest tightness, severe back pain, and unresponsiveness. The presence of two life-threatening reactions demonstrates that a low overall incidence does not imply low clinical importance. The immediate interruption of infusion and prompt symptomatic treatment were followed by recovery in every affected patient. Seven patients were able to continue or undergo cautious rechallenge, while one patient was changed to another regimen. No reaction-related death occurred.

Overall, the findings emphasize a structured clinical approach: appropriate premedication, careful observation at the beginning of infusion, rapid recognition of symptoms, immediate stopping of paclitaxel when a reaction is suspected, severity-based supportive treatment, and individualized decisions regarding rechallenge or regimen change. This approach was associated with favourable immediate outcomes in the study cohort.

5. CONCLUSION

Paclitaxel-associated immediate hypersensitivity reactions occurred in 8 of 250 chemotherapy cycles, giving an incidence of 3.2%. Reactions were concentrated in the early infusion period, and 50% occurred during the first treatment cycle. Three reactions were mild, three were severe, and two were life-threatening. Immediate interruption of paclitaxel and severity-based supportive management resulted in recovery of all affected patients, with seven continuing or undergoing cautious rechallenge and one changing regimen. Premedication and close monitoring, especially during the first minutes and early cycles, remain essential components of safe paclitaxel administration.

REFERENCES

1. PubMed. Record PMID: 33068367. Available from: https://pubmed.ncbi.nlm.nih.gov/33068367/
2. Journal of Clinical Oncology. Available from: https://ascopubs.org/journal/jco
3. Improvement of paclitaxel-associated adverse reactions via the use of nano-based drug delivery systems. International Journal of Nanomedicine. Available from: https://www.dovepress.com/improvement-of-paclitaxel-associated-adverse-reactions-adrs-via-the-us-peer-reviewed-fulltext-article-IJN
4. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006;155(2):401–407.
5. Kallini JR, Hamed N, Khachemoune A. Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. Int J Dermatol. 2015;54(2):130–140.
6. Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr. 2010;2010(41):134–138.
7. Sgroi DC. Preinvasive breast cancer. Annu Rev Pathol. 2010;5:193–221.
8. Kaveh F, Baumbusch LO, Nebdal D, Børresen-Dale AL, Lingjærde OC, Edvardsen H, et al. A systematic comparison of copy number alterations in four types of female cancer. BMC Cancer. 2016;16:1–15.
9. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197.
10. Boggess JF, Kilgore JE, Tran AQ. Uterine cancer. In: Abeloff’s Clinical Oncology. Elsevier; 2020. p. 1508–1524.
11. PubMed. Record PMID: 7865431. Available from: https://pubmed.ncbi.nlm.nih.gov/7865431/
12. Cleveland Clinic. Paclitaxel injection. Available from: https://my.clevelandclinic.org/health/drugs/20273-paclitaxel-injection
13. PubMed. Record PMID: 25519756. Available from: https://pubmed.ncbi.nlm.nih.gov/25519756/
14. Standardized titration protocol reduces the incidence of paclitaxel infusion-related hypersensitivity reactions. ResearchGate. Available from: https://www.researchgate.net/publication/375116442_Standardized_Titration_Protocol_Reduces_the_Incidence_of_Paclitaxel_Infusion-Related_Hypersensitivity_Reactions
15. Stoll P, Kopittke L. Potential drug–drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study. Int J Clin Pharm. 2015;37:475–484